Medtronic Expands Minimally Invasive Spine Surgery Ecosystem with Next-Generation Spinal Technologies

Medtronic plc (NYSE: MDT), the global leader in medical technology, today announced the latest additions to its minimally invasive spine surgery ecosystem, making it the only company to combine spinal implants, biologics, navigation, robotics, and AI-powered data to surgeons and patients.

New additions to the Medtronic MIS+ portfolio include:

  • Catalyft™ PL and PL40 , the first releases in the new Catalyft™ Expandable Interbody System. Catalyft™ PL and PL40 feature a unique design for anterior rim engagement, a beveled tip for ease of insertion, seamless integration with StealthStation™ Navigation, simplified bone graft delivery, and active expansion at the precise angle and lift that surgeons need for minimally invasive, patient-specific solutions to meet sagittal alignment goals.
  • The Space-D™ Access System, which enables pedicle-screw-based distraction, retraction and compression, compatible with Medtronic's leading MIS screw system, CD Horizon™ Solera™ Voyager™, enabling simpler, all-in-one access for surgeons, making procedures more efficient and reproducible.
  • Accelerate™ Graft Delivery System with Grafton™ DBF enables more controlled and efficient delivery of graft material into the disc space or other locations. Accelerate enables placement of more bone graft 2 to facilitate fusion and is nine-times faster than traditional graft delivery methods. 3 Bone grafting is also more controlled and easier for surgeons to visualize.

"At Medtronic, we continue to raise the bar in minimally invasive spine surgery through our commitment to driving innovation and expanding our MIS capabilities," said Carlton Weatherby , vice president and general manager of Spine & Biologics within the Cranial & Spinal Technologies business, which is part of the Neuroscience Portfolio at Medtronic. "Our seamless integration of implants, instrumentation, and enabling technologies into a single ecosystem is helping surgeons remove variability in the surgical procedure, streamline and personalize care, and enable better patient outcomes."

Advancing Care with MIS+ TLIF
More than 450,000 spinal fusion procedures 4 are performed in the United States each year to reduce pain, improve stability, or correct deformities of the spine. About 200,000 are lower or lumbar fusion procedures, 5 which treat conditions such as degenerative disc disease, herniated disc, fractured vertebrae, spinal stenosis, and other conditions. One of the most common spinal fusion procedures is transforaminal lumbar interbody fusion (TLIF). During a TLIF procedure, a disc is removed from the lumbar spine, and two vertebrae are joined together using screws or rods. An interbody fusion spacer is inserted into the space, and a bone graft or bone substitute is placed into the space. As the bone heals, it fuses the vertebrae together to form one bone.

The new additions to Medtronic's MIS+ portfolio create the most complete MIS+ TLIF solution available for surgeons. A complete procedural solution allows surgeons to provide the benefits of minimally invasive spine care – including lower infection and complication rates, 1 less blood loss, 1 smaller incisions, reduced hospital stays, 1 and less pain 6 – to more patients. Compared to open TLIF, MIS+TLIF requires a smaller incision and less muscle and tissue disruption, which can mean a faster recovery time after the operation. 7, 8, 9 Together, these technologies improve clinical and economic value while reducing OR time with a fully streamlined procedure 1 .

"Medtronic's comprehensive ecosystem of MIS technologies is developing a new standard for TLIF and other spine procedures," said Christopher Holland , M.D., Ph.D. of Carolina Neurosurgery and Spine Associates. "While minimally invasive procedures can present a learning curve for surgeons, Medtronic's portfolio makes these operations efficient and reproducible, utilizing instruments as in an open procedure, with the additional benefits of AI, navigation and robotics. The MIS ecosystem overall helps make these procedures safer, and my patients can recover faster and return home sooner (often without requiring a hospital admission), with a better overall care experience and better outcomes."

For more information, visit www.medtronic.com/MIS .

About Medtronic
Medtronic plc ( www.medtronic.com ), headquartered in Dublin, Ireland , is among the world's largest medical technology, services, and solutions companies – alleviating pain, restoring health, and extending life for millions of people around the world. Medtronic employs more than 90,000 people worldwide, serving physicians, hospitals, and patients in more than 150 countries. The company is focused on collaborating with stakeholders around the world to take healthcare Further, Together.

Any forward-looking statements are subject to risks and uncertainties such as those described in Medtronic's periodic reports on file with the Securities and Exchange Commission. Actual results may differ materially from anticipated results.  

References

  1. Clinical and economic value: Vertuani, S., et al., A Cost-Effectiveness Analysis of Minimally Invasive versus Open Surgery Techniques for Lumbar Spinal Fusion in Italy and the United Kingdom . Value in Health, 2015. 18(6):p. 810-816.
  2. Compared to autograft alone using traditional graft delivery methods based on benchtop testing.
  3. Based on benchtop testing.
  4. "2018 U.S. National Inpatient Stays Maternal/Neonatal Stays Included." Healthcare Cost and Utilization Project. Agency for Healthcare Research and Quality. April 21, 2021 . https://www.hcup-us.ahrq.gov/faststats/NationalProceduresServlet . Accessed Aug. 3, 2021 .
  5. Martin B, Mirza S, et al. Trends in Lumbar Fusion Procedure Rates and Associated Hospital Costs for Degenerative Spinal Diseases in the United States , 2004 to 2015. Spine ( Phila Pa 1976). 2019 Mar 1 ;44(5):369-376. doi: 10.1097/BRS.0000000000002822.
  6. Djurasovic M,. et al., Clinical Outcomes of Minimally Invasive Versus Open TLIF: A Propensity Matched Cohort Study. Am J Orthop ( Belle Mead NJ ). 2016 Mar-Apr;45(3):E77-82.
  7. Goldstein, C.L., et al., Perioperative outcomes and adverse events of minimally invasive versus open posterior lumbar fusion: Meta-analysis and systematic review. Journal of Neurosurgery: Spine, 2016. 24(3): p. 416-427.
  8. Goldstein, C.L., et al., Comparative Effectiveness and Economic Evaluations of Open Versus Minimally Invasive Posterior or Transforaminal Lumbar Interbody Fusion. Spine, 2016. 41: p.s74-s89.
  9. Tan, J.H., et al., Is MIS-TLIF superior to open TLIF in obese patients?: A systematic review and meta-analysis. European Spine Journal, 2018. 27(8): p. 1877-1886.

Contacts:




Donna Marquard

Ryan Weispfenning

Public Relations

Investor Relations

+1-763-526-6248

+1-763-505-4626

Medtronic plc (PRNewsfoto/Medtronic plc)

Cision View original content to download multimedia: https://www.prnewswire.com/news-releases/medtronic-expands-minimally-invasive-spine-surgery-ecosystem-with-next-generation-spinal-technologies-301388542.html

SOURCE Medtronic plc

News Provided by Canada Newswire via QuoteMedia

The Conversation (0)
Novel Diagnostic Technology Disrupting Diabetic Retinopathy Market Generating Billions in Revenue Opportunities

Novel Diagnostic Technology Disrupting Diabetic Retinopathy Market Generating Billions in Revenue Opportunities

FN Media Group News Commentary - The global diabetic retinopathy market has shown a consistent growth in recent years and is expected to continue for the coming several years. According to a report , Grand View Research said that the global diabetic retinopathy market size was estimated at USD 9.48 billion in 2024 and is expected to grow at a CAGR of 6.4% from 2025 to 2030. One of the main factors expected to fuel market expansion is the growing incidence of diabetes in older individuals and the rising prevalence of blindness caused by diabetes. The introduction of novel diagnostic technologies and treatments and the increased awareness are driving the market expansion. The report said: "Diabetes is a globally prevalent health concern. It can result in Diabetic Retinopathy (DR), which is caused by damage to the blood vessels in the retina. DR leads to blurred vision and vision loss in most cases. International Diabetes Federation estimates that 1 in 8 adults will be living with diabetes in 2050. It also states urbanization, an aging population, decreasing physical activity, and the growing prevalence of obesity are some of the key aspects contributing to the rise in type 2 diabetes. DR is a serious microvascular complication of type I and type II diabetes. It is often caused by prolonged high blood sugar levels that damage the blood vessels in the retina. It can progress to sight-threatening stages, which can cause blindness and visual impairment if not treated. According to a report published by the WHO, DR is responsible for 4.8% of the 37 million blindness cases in the world. The prevalence of this condition in the U.S. is expected to increase rapidly. Despite all the necessary measures adopted by the diabetic population, DR can lead to permanent blindness based on the disease stage and severity of the condition. Active healthcaretech companies active in the markets include: Avant Technologies Inc. (OTCQB: AVAI), Tandem Diabetes Care, Inc. (NASDAQ: TNDM), Novo Nordisk AS (NYSE: NVO), Insulet Corporation (NASDAQ: PODD), Medtronic plc (NYSE: MDT).

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less
Medtronic chairman and CEO Geoff Martha to speak at Bernstein's Strategic Decisions Conference

Medtronic chairman and CEO Geoff Martha to speak at Bernstein's Strategic Decisions Conference

Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced it will participate in Bernstein's 41st Strategic Decisions Conference on Thursday, May 29, 2025 .

Geoff Martha , Medtronic chairman and chief executive officer, will make a formal presentation beginning at 11:00 a.m. EDT ( 10:00 a.m. CDT ). Immediately following the presentation, Martha will be joined by Thierry Piéton, Medtronic executive vice president and chief financial officer, to answer questions about the company.

News Provided by Canada Newswire via QuoteMedia

Keep reading...Show less
Medtronic reports strong finish to its fiscal year with its fourth quarter financial results; announces dividend increase

Medtronic reports strong finish to its fiscal year with its fourth quarter financial results; announces dividend increase

Building momentum in key franchises including Pulsed Field Ablation, TAVR, Cardiac Rhythm Management, Diabetes, Spine, and Neuromodulation

Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced financial results for its fourth quarter (Q4) and fiscal year 2025 (FY25), which ended April 25, 2025 .

News Provided by PR Newswire via QuoteMedia

Keep reading...Show less
Medtronic announces intent to separate Diabetes business

Medtronic announces intent to separate Diabetes business

Enables intense focus on highest margin growth drivers where Medtronic has leading core competencies

Leading, scaled, direct-to-consumer Diabetes business poised to become standalone company; only company with a complete ecosystem to address intensive insulin management

News Provided by Canada Newswire via QuoteMedia

Keep reading...Show less
Orchestra BioMed Reports First Quarter 2025 Financial Results and Highlights Recent Regulatory and Clinical Milestones

Orchestra BioMed Reports First Quarter 2025 Financial Results and Highlights Recent Regulatory and Clinical Milestones

  • FDA Breakthrough Device Designation Awarded to AVIM Therapy
  • FDA IDE Approved for Virtue SAB U.S. Pivotal Trial for Launch

Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO, "Orchestra BioMed" or the "Company"), a biomedical company accelerating high-impact technologies to patients through risk-reward sharing partnerships, today announced financial results for the first quarter ended March 31, 2025, and provided a business update highlighting continued regulatory momentum, disciplined operational execution, and a strengthening clinical development pipeline.

Q1 2025 Highlights:

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less
Medtronic to announce financial results for its fourth quarter and full fiscal year 2025

Medtronic to announce financial results for its fourth quarter and full fiscal year 2025

Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced that it will report financial results for its fourth quarter and full fiscal year 2025 on Wednesday, May 21, 2025 . A news release will be issued at approximately 5:45 a.m. Central Daylight Time (CDT) and will be available at https:news.medtronic.com . The news release will include summary financial information for the company's fourth quarter and full fiscal year 2025, which ended on Friday, April 25, 2025 .

Medtronic will host a video webcast at 7:00 a.m. CDT on May 21, 2025 , to discuss results for its fourth quarter and full fiscal year 2025. The webcast can be accessed at https://investorrelations.medtronic.com .

News Provided by Canada Newswire via QuoteMedia

Keep reading...Show less

Latest Press Releases

Related News

×